Revolution Medicines (RVMD) Capital Expenditures (2019 - 2026)
Revolution Medicines' quarterly Capital Expenditures came in at $786000.0 in Q1 2026, down 71.78% year-on-year from $2.8 million in Q1 2025, and up 73.13% quarter-over-quarter from $454000.0 in Q4 2025.
Revolution Medicines has reported Capital Expenditures for 8 years, with the latest figure at $786000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 71.78% year-over-year to $786000.0; the trailing twelve-month figure through Mar 2026 stood at -$123000.0 (down 101.1% YoY), and the FY2025 full-year result was $1.9 million, down 81.8% from the prior year.
- Capital Expenditures for Q1 2026 stood at $786000.0, up from $454000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $7.9 million in Q2 2025, with the low at -$9.3 million in Q3 2025.
- Average Capital Expenditures over 5 years is $1.0 million, with a median of $1.3 million recorded in 2023.
- Year-over-year, Capital Expenditures soared 2682.47% in 2022 and plunged 364.03% in 2025.
- Tracing RVMD's Capital Expenditures over 5 years: stood at -$6.5 million in 2022, then surged by 119.66% to $1.3 million in 2023, then decreased by 4.68% to $1.2 million in 2024, then slumped by 62.85% to $454000.0 in 2025, then surged by 73.13% to $786000.0 in 2026.
- The last three Capital Expenditures figures came in at $786000.0 (Q1 2026), $454000.0 (Q4 2025), and -$9.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 786,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 786,000.00 |
| Mar 31, 2026 | 786,000.00 |
| Dec 31, 2025 | 454,000.00 |
| Dec 31, 2025 | 454,000.00 |
| Sep 30, 2025 | -9.29 Mn |
| Sep 30, 2025 | -9.29 Mn |
| Jun 30, 2025 | 7.93 Mn |
| Jun 30, 2025 | 7.93 Mn |
| Mar 31, 2025 | 2.79 Mn |
| Mar 31, 2025 | 2.79 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Sep 30, 2024 | 3.52 Mn |
| Sep 30, 2024 | 3.52 Mn |
| Jun 30, 2024 | 3.68 Mn |
| Jun 30, 2024 | 3.68 Mn |
| Mar 31, 2024 | 1.89 Mn |
| Mar 31, 2024 | 1.89 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Sep 30, 2023 | -1.55 Mn |
| Sep 30, 2023 | -1.55 Mn |
| Jun 30, 2023 | 1.12 Mn |
| Jun 30, 2023 | 1.12 Mn |
| Mar 31, 2023 | 1.76 Mn |
| Mar 31, 2023 | 1.76 Mn |
| Dec 31, 2022 | -6.52 Mn |
| Dec 31, 2022 | -6.52 Mn |
| Sep 30, 2022 | 5.01 Mn |
| Sep 30, 2022 | 5.01 Mn |
| Jun 30, 2022 | 1.26 Mn |
| Jun 30, 2022 | 1.26 Mn |
| Mar 31, 2022 | 1.67 Mn |
| Mar 31, 2022 | 1.67 Mn |
| Dec 31, 2021 | 6.48 Mn |
| Dec 31, 2021 | 6.48 Mn |
| Sep 30, 2021 | -194,000.00 |
| Sep 30, 2021 | -194,000.00 |
| Jun 30, 2021 | -644,000.00 |
| Jun 30, 2021 | -644,000.00 |
| Mar 31, 2021 | 882,000.00 |
| Mar 31, 2021 | 882,000.00 |
| Dec 31, 2020 | 1.37 Mn |
| Dec 31, 2020 | 1.37 Mn |
| Sep 30, 2020 | -89,000.00 |
| Sep 30, 2020 | -89,000.00 |
| Jun 30, 2020 | -73,000.00 |
| Jun 30, 2020 | -73,000.00 |
| Mar 31, 2020 | 603,000.00 |
| Mar 31, 2020 | 603,000.00 |
| Dec 31, 2019 | 126,000.00 |
| Dec 31, 2019 | 126,000.00 |
| Sep 30, 2019 | -656,000.00 |
| Sep 30, 2019 | -656,000.00 |
| Jun 30, 2019 | 569,000.00 |
| Jun 30, 2019 | 569,000.00 |
| Mar 31, 2019 | 341,000.00 |
| Mar 31, 2019 | 341,000.00 |